Results 111 to 120 of about 333,306 (159)

Human antibodies in Mexico and Brazil neutralizing tick-borne flaviviruses. [PDF]

open access: yesCell Rep
Cervantes Rincón T   +29 more
europepmc   +1 more source

Correction: Colorectal anastomotic safety assessment using ICG fluorescence and flexible endoscopy (COLOSSEUM): a global survey of 1367 surgeons. [PDF]

open access: yesSurg Endosc
Belvedere A   +10 more
europepmc   +1 more source

Real-world challenges in hepatocellular carcinoma in Central America and the Caribbean: insights from a multinational expert survey. [PDF]

open access: yesFront Oncol
Perelló C   +14 more
europepmc   +1 more source

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. [PDF]

open access: yesCancer Immunol Immunother
Kopp RM   +34 more
europepmc   +1 more source

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network. [PDF]

open access: yesJ Neurol Neurosurg Psychiatry
Lorscheider J   +46 more
europepmc   +1 more source

How Internet use relates to mental health in older adults: findings from the Czech Republic and the Republic of Slovenia. [PDF]

open access: yesFront Public Health
Klun M   +6 more
europepmc   +1 more source

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. [PDF]

open access: yesCancer Immunol Immunother
Porta C   +30 more
europepmc   +1 more source

RoCK and ROI: single-cell transcriptomics with multiplexed enrichment of selected transcripts and region-specific sequencing. [PDF]

open access: yesNat Commun
Moro G   +16 more
europepmc   +1 more source

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). [PDF]

open access: yesCancer Immunol Immunother
Santoni M   +35 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy